DEPLOYDatabase

Partnership

Siemens Healthineers x Stryker

On Sep 17 2025 Siemens Healthineers and Stryker announced a strategic partnership to develop a robotic system for elective and emergency neurovascular procedures including stroke and aneurysm treatment. The joint release says the work combines Siemens Healthineers robotics and image-guided therapy with Stryker neurovascular devices, covering robotic system design, access device and implant integration, imaging for robotic navigation, and workflow optimization.

The initial phase focuses on co-developing the ecosystem and clinical validation with physicians. Quotes include Carsten Bertram (Siemens Healthineers Advanced Therapies) and Jim Marucci (Stryker Neurovascular). This is a development partnership announcement, not a cleared commercial product (Siemens Healthineers).

technology · Active · just announced


Machine-readable surfaces

ea347984-2b32-49b0-b38b-e56f64b0fac6
Type
technology
Status
Activejust announced
Announced
2025-09-17
1.1 years ago
Active for
1.1 years

Who’s involved

Medical imaging and diagnostics; MRI, CT, X-ray, and laboratory diagnostics. Public company (ETR: SHL).

HQErlangen, Germanysiemens-healthineers.com1 partnerships

Most-frequent partners

Strykerco developer

Stryker Corporation (NYSE: SYK) is one of the [World](/companies/world-labs)'s largest medical technology companies, headquartered in Kalamazoo, Michigan, with $25B in 2025 revenue and approximately 56,000 employees. The company's Mako SmartRobotics platform is the leading robotic orthopedic surgery system, with record Mako installations in 2024 for hip and knee replacements, and the next-generation Mako showcased at AAOS 2025 including the new Mako Shoulder application.

HQKalamazoo, MI, USAstryker.com4 partnerships

Related partnerships

Recent partnerships of the same kind

Sources (1)

  1. https://www.siemens-healthineers.com/press/releases/stryker-partnership

Deploy Watch

Track this partnership.

We notify you when the status changes against primary-source evidence, expansion is verified, or the partnership is terminated.